In the article, “TACE/ADAM17 Is Essential for Oligodendrocyte Development and CNS Myelination,” by Javier Palazuelos, Howard C. Crawford, Michael Klingener, Bingru Sun, Jason Karelis, Elaine W. Raines, and Adan Aguirre, which appeared on pages 11884–11896 of the September 3, 2014 issue, the experimental procedure of BrdU administration was described inconsistently. In the conducted experiment, mice were injected at postnatal day 6 (P6) and 3 h later received tamoxifen (TAM) injections for 2 consecutive days; tissue was analyzed at 24 h after the last TAM injection (at P9). The published article noted that the analysis occurred 48 h after the final TAM injection. Two specific corrections are required to resolve these inconsistencies.
In Figure 3K, P7 and P8 should appear as P8 and P9, respectively. The figure legend published correctly. A revised figure appears below.
On page 11885, in the Materials and Methods subsection “BrdU administration in vivo,” the last sentence should instead read: “For cell cycle exit studies, BrdU was injected first and 3 h later mice received TAM for 2 d and tissue was analyzed 24 h later to quantify the percentage of OPs that exit the cell cycle (BrdU+Ki67–/BrdU+ cells) (Palazuelos et al., 2012).”
Additionally, Figure 5E was duplicated from unrelated data in an earlier publication (Palazuelos et al., 2014, our Fig. 5J). The authors state that the data presented in Figure 5E are not required to support the conclusions of the paper; Figure 2E demonstrates the same result in PDGFRα-Cretm:TACEfl/fl mice.
The authors regret these errors.
